Compare RPRX & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | DGX |
|---|---|---|
| Founded | 1996 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 23.2B |
| IPO Year | 2020 | 1996 |
| Metric | RPRX | DGX |
|---|---|---|
| Price | $58.55 | $236.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $51.40 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | ★ 1.90% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 0.71 | ★ 5.08 |
| Revenue | $2,378,193,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $38.63 | $7.53 |
| Revenue Next Year | $4.73 | $3.77 |
| P/E Ratio | $83.41 | ★ $46.81 |
| Revenue Growth | 5.06 | ★ 11.78 |
| 52 Week Low | $34.63 | $171.18 |
| 52 Week High | $60.44 | $240.13 |
| Indicator | RPRX | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 68.54 |
| Support Level | $55.66 | $191.82 |
| Resistance Level | $58.84 | $240.13 |
| Average True Range (ATR) | 1.42 | 4.61 |
| MACD | -0.11 | -0.26 |
| Stochastic Oscillator | 46.94 | 74.22 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.